摘要
目的分析信迪利单抗联合TP方案治疗Ⅲb~Ⅳ期非小细胞肺癌(NSCLC)患者的效果。方法选取70例Ⅲb~Ⅳ期NSCLC患者,按随机数表法分为两组,均35例。对照组行TP方案治疗,观察组加以信迪利单抗治疗。比较两组临床疗效、肿瘤标志物、免疫功能、健康状况、不良反应。结果观察组治疗总有效率为77.14%(27/35),高于对照组的54.29%(19/35);治疗后的各肿瘤标志物分别为(10.53±1.21)ng/ml、(0.52±0.06)μg/L、(40.32±2.05)U/ml、(8.21±1.24)U/ml,CD8+为(20.54±1.88),低于对照组的(15.26±2.08)ng/ml、(0.73±0.10)μg/L、(46.89±3.21)U/ml、(10.15±1.69)U/ml、(29.77±2.30),CD3+为(65.94±7.96)%、CD4+为(39.77±4.83)%、CD4+/CD8+为(1.94±0.31)、NK细胞为(26.98±2.48)%、KPS评分为(77.95±6.42)分,高于对照组的(52.36±4.77)%、(30.22±3.01)%、(1.02±0.18)、(21.75±1.69)%、(68.63±5.39)分,有统计学差异(P<0.05);两组不良反应对比无差异(P>0.05)。结论信迪利单抗联合TP方案能降低Ⅲb~Ⅳ期NSCLC患者肿瘤标志物,调节免疫功能,有助于健康状况的改善,且无严重不良反应。
Objective To analyze the efficacy of Xindilimumab combined with TP regimen in the treatment of stageⅢb~Ⅳnon-small cell lung cancer(NSCLC)patients.Methods 70 patients with stageⅢb~ⅣNSCLC were selected and randomly divided into 2 groups using a random number table,with 35 patients in each group.The control group was treated with TP regimen,while the observation group was treated with xindilimab.Compare the clinical efficacy,tumor markers,immune function,health status,and adverse reactions between the 2 groups.Results The total effective rate of the observation group was 77.14%(27/35),which was higher than the 54.29%(19/35)of the control group;The post-treatment tumor markers were(10.53±1.21)ng/ml,(0.52±0.06)μg/L,(40.32±2.05)U/ml,(8.21±1.24)U/ml,and CD8^(^(+))was(20.54±1.88),which was lower than the control group's(15.26±2.08)ng/ml,(0.73±0.10)μg/L,(46.89±3.21)U/ml,(10.15±1.69)U/ml,(29.77±2.30),CD3^(^(+))was(65.94±7.96)%,CD4^(^(+))was(39.77±4.83)%,CD4^(^(+))/CD8^(^(+))was(1.94±0.31).The NK cell count was(26.98±2.48)%,and the KPS score was(77.95±6.42)points,which were higher than those of the control group(52.36±4.77)%,(30.22±3.01)%,(1.02±0.18)%,(21.75±1.69)%,and(68.63±5.39)points,with statistical differences(P<0.05);There was no significant difference in adverse reactions between the 2 groups(P>0.05).Conclusion The combination of Xindilimumab and TP regimen can reduce tumor markers,regulate immune function,and improve health status in stageⅢb~ⅣNSCLC patients without serious adverse reactions.
作者
张轩斌
彭飞
金博
ZHANG Xuanbin;PENG Fei;JIN Bo(Nanyang Central Hospital,Nanyang,473000)
出处
《实用癌症杂志》
2025年第11期1826-1829,共4页
The Practical Journal of Cancer
关键词
非小细胞肺癌
信迪利单抗
免疫功能
不良反应
Non-small cell lung cancer
Sindilimab
Immune function
Adverse reaction
